FBT
First Trust NYSE Arca Biotechnology Index Fund · PSE
- Category Equity
- Expense Ratio 0.56%
- Listing Date Jun 23, 2006
- Volume 13,230.0
- Market Cap (AUM) $1,099.49M
Performance
-2.36%
1W
+2.48%
1M
-0.85%
3M
-3.38%
6M
-3.38%
YTD
+0.19%
1Y
Top Holdings
-
Name
Symbol%Assets
- United Therapeutics CorporationUTHR4.29%
- Halozyme Therapeutics, Inc.HALO4.26%
- Moderna, Inc.MRNA4.13%
- Corcept Therapeutics Incorporated.CORT4.04%
- Vertex Pharmaceuticals IncorporatedVRTX3.84%
- Amgen Inc.AMGN3.75%
- Incyte CorporationINCY3.74%
- Regeneron Pharmaceuticals, Inc.REGN3.73%
- Mettler-Toledo International Inc.MTD3.73%
- Intra-Cellular Therapies, Inc.ITCI3.70%
Technical Analysis of FBT 2024-05-31
Overview:
In analyzing the technical indicators for FBT stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions to guide inv...
Recent News & Updates
- 2016-11-09 01:52
- 2016-11-09 00:04
What Drove Regenerons 3Q16 Performance?(Marketrealist)
- 2016-11-08 04:49
- 2016-11-08 02:26
Biotech ETFs Slumping on Q3 Results(Yahoo Finance)
- 2016-11-01 22:05
Strensiq: A Potential Driver for Alexion(Marketrealist)
- 2016-10-26 20:34
Once Beloved Momentum ETF Loses Its Momo(Yahoo Finance)
- 2016-10-20 01:57
- 2016-10-19 20:06
What Are the Drivers behind the Success of Soliris?(Marketrealist)
- 2016-10-18 22:05
Why Europe Is an Important Market for Vertexs Orkambi(Marketrealist)
- 2016-09-29 00:04
How Regeneron Is Working to Maintain Eyleas Dominance(Marketrealist)
- 2016-09-27 04:05
BioMarin to Cross $1 Billion Revenue in 2016(Marketrealist)
- 2016-09-26 07:04
Higher Discontinuations Are among Orkambis Concerns(Marketrealist)
- 2016-09-20 02:49
How Ionis Pharmaceuticals Valuation Compares to Its Peers(Marketrealist)
- 2016-09-19 02:08
- 2016-09-14 02:19
Inside the Recent Surge in Biotech ETFs(Yahoo Finance)
Page 3 of 3
previousnext